T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,632,303 shares of Dianthus Therapeutics Inc. common stock, representing 12.1% of the class. The firm holds sole voting power over 6,454,315 shares and sole dispositive power over 6,632,303 shares, with no shared voting or dispositive power. T. Rowe Price Investment Management, Inc. states that this report should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.
DIANTHUS THERAPEUTICS INC reported that T. Rowe Price Investment Management, Inc. holds a significant position in its common stock. T. Rowe Price Investment Management is shown as beneficially owning 3,888,456 shares of common stock, representing 7.1% of the outstanding class.
The firm reports sole voting power over 3,884,903 shares and sole dispositive power over 3,888,456 shares, with no shared voting or dispositive power. T. Rowe Price Investment Management states that this filing should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Dianthus Therapeutics, a clinical-stage biotech focused on severe autoimmune diseases, reported a net loss of $50.2M for the quarter and $91.0M for the six months ended June 30, 2026, driven mainly by rising R&D spending on its claseprubart program and discovery work.
R&D expenses reached $48.7M in the quarter and $83.2M year-to-date, while G&A totaled $13.6M and $26.0M, respectively. License revenue from its Tenacia partnership contributed $0.8M in the quarter. A March 2026 equity offering raised $719.0M, alongside ATM share sales of $58.7M, lifting liquidity, with cash and cash equivalents of $110.5M and marketable securities of $1.08B within total assets of $1.21B at June 30, 2026. Management states that existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financial statement issuance date, even as the company continues to invest heavily in claseprubart, new candidate DNTH212 and broader pipeline activities.
Dianthus Therapeutics, Inc. reported second-quarter 2026 results and highlighted progress across its autoimmune pipeline. Lead asset claseprubart, a subcutaneous aC1s inhibitor, advanced with initiation of the Phase 3 EMERGE registrational trial in generalized myasthenia gravis, with top-line results anticipated in 2H 2028. In chronic inflammatory demyelinating polyneuropathy, the Phase 3 CAPTIVATE trial showed a 75% response rate in an interim analysis of the first 40 Part A participants, exceeding the 50% target, and the Phase 2 MoMeNtum trial in multifocal motor neuropathy completed enrollment above its 36-patient target, with 46 patients and top-line data expected in December 2026.
The company is building a rheumatology franchise with DNTH212, with Phase 1 healthy volunteer data anticipated by year-end 2026, and advancing DNTH312, a next-generation bifunctional fusion protein aiming to be Phase 1 ready by year-end 2027. Cash, cash equivalents and investments totaled approximately $1.2 billion as of June 30, 2026, providing expected runway into 2030. For the quarter, research and development expenses were $48.7 million and general and administrative expenses were $13.6 million. Net loss was $50.2 million, or $0.90 per share, compared with $31.6 million, or $0.88 per share, in the prior-year quarter.
BlackRock, Inc. filed Amendment No. 1 to a Schedule 13G reporting its beneficial ownership in Dianthus Therapeutics Inc. common stock. BlackRock reports beneficial ownership of 3,504,166 shares of common stock, representing 6.4% of the outstanding class as of June 30, 2026.
BlackRock has sole voting power over 3,433,718 shares and sole dispositive power over 3,504,166 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds, but no single person’s interest exceeds 5% of Dianthus’s outstanding common shares.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options for 31,249 shares of common stock at $21.77 per share on July 9, 2026, then sold the 31,249 shares in three open-market transactions at weighted average prices of $100.22, $101.24 and $101.97 pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. Following these sales, he reported no directly held common shares and reported holdings of 68,751 stock options from an award that vests in equal monthly installments over four years after May 1, 2024.
Dianthus Therapeutics SVP and General Counsel Adam M. Veness reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 30,000 shares of common stock at a strike price of $17.88 per share, then sold 30,000 shares in open-market trades at weighted average prices of $80.34 and $81.38 per share. These sales were executed under a Rule 10b5-1 trading plan. Following the transactions, he held no shares of common stock directly but retained 80,000 stock options that continue to vest over four years beginning January 1, 2024.
Dianthus Therapeutics posted an updated corporate presentation highlighting new clinical and strategic data for its autoimmune pipeline. The company reported an interim responder analysis from Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy, where 75% of the first 40 participants who completed Part A were confirmed responders based on adjusted INCAT improvement. The presentation also detailed Phase 2 MaGic trial results in generalized myasthenia gravis, showing statistically significant and clinically meaningful improvements versus placebo across multiple endpoints, including MG-ADL, QMG, MGC, MG-QoL-15r and Minimal Symptom Expression at Week 13 for the 300mg/2mL dose. Claseprubart was generally well tolerated in Phase 1 and 2 with no signal of encapsulated bacterial infections or clinical symptoms of drug-induced lupus, supporting a target profile without a boxed warning or REMS. Dianthus additionally highlighted DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor in Phase 1, and reported cash, cash equivalents and investments of about $1.2B as of March 31, 2026 with runway expected into 2030.